Loading
Latest filing published 13 Mar 2026 for ONCOLYTICS BIOTECH INC, €8,871. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
This profile gathers the share dealings of James T. Parsons across 2 companies, led by DiaMedica Therapeutics Inc. and Oncolytics Biotech Inc. Over a trading history stretching from 3 January 2022 to 11 March 2026, the count stands at 6 filings.
On the market, this insider has only ever bought: 1 purchase, €8,871 in total. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Other entries cover 4 share grants and 1 option exercise. Since January 2026: 1 purchase and no sales on the market.
The record was last updated on 13 March 2026 with an open-market purchase (€8,871) in Oncolytics Biotech Inc. Typically, a trade is published a median of 3 days after it takes place. The legal deadline for a Form 4 is two business days after the transaction. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
6 of 6 declarations